logo
Share SHARE
FONT-SIZE Plus   Neg

Ipsen Renegotiates 2010 Strategic Partnership Agreement With Inspiration

Ipsen (IPSEF.PK) announced the renegotiation of its 2010 strategic partnership agreement with Inspiration Biopharmaceuticals, Inc. for the development and commercialization of Inspiration's recombinant product portfolio - OBI-1, a recombinant porcine factor VIII (rpFVIII) being developed for treating patients with acquired hemophilia A and congenital hemophilia A with inhibitors, and IB1001, a recombinant factor IX (rFIX) for the treatment and prevention of bleeding in patients with hemophilia B.

As per the new agreement and in its territories, Ipsen recovers commercial rights to OBI-1. Also, Ipsen is granted commercial rights for IB1001. As a result, Ipsen will record sales of OBI-1 and IB1001 in its drug sales line. Ipsen will further pay Inspiration a mid-teen royalty on OBI-1 sales and a higher double digit royalty on IB1001's sales.

In addition, under the new terms, Ipsen has agreed to invest up to $20 million in Inspiration.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Alteryx, Inc., a provider of self-service data analytics software, is the latest tech company to go public in March. Alteryx said it has priced its IPO of 9 million shares of its Class A common stock at $14 per share, at the top end of its range of $12 to $14 per share. Dunkin' Donuts is bidding adieu to one of its frozen coffee beverages this summer. However, loyal fans of the decades-old menu staple have not taken kindly to the news. The coffee chain said it will discontinue its popular Coffee Coolatta beverage this summer and instead, introduce the new Frozen Dunkin' Coffee, made with coffee extract, sugar and milk. Canadian pipeline operator Enbridge Inc. said it will cut about 1,000 jobs, or six percent of its workforce, following the completion of its acquisition of Houston-based Spectra Energy Corp. The job cuts will take place across the merged company.
comments powered by Disqus
Follow RTT